Trial Profile
Phase II trial of gemcitabine and cisplatin/carboplatin (GC) plus erlotinib in patients with recurrent and/or metastatic nasopharyngeal cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Mar 2019
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Carboplatin; Cisplatin; Gemcitabine
- Indications Carcinoma; Nasopharyngeal cancer; Squamous cell cancer
- Focus Therapeutic Use
- 14 Jul 2011 Actual end date (Apr 2011) added as reported by ClinicalTrials.gov.
- 14 Jul 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 Feb 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.